2nd Quarter - Amendment

ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

Firm
Client
Income
—
Expenses
$520,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 21, 2014 $480,000 Replaced
2nd Quarter - Amendment Jul 22, 2014 $480,000 Replaced
2nd Quarter - Amendment Aug 19, 2014 $520,000 Replaced
2nd Quarter - Amendment (this page) Jun 10, 2015 $520,000 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Intellectual property and issues in China and potential impact on US entities

LobbyistCovered position, as disclosed
BRADLEY ALLEN ROSSIN —

Contacted: Patent & Trademark Office (PTO); SENATE; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); State, Dept of (DOS)

Taxation/Internal Revenue Code TAX

HR 4679 Stop Corporate Inversions Act of 2014, S 2360 Stop Corporate Inversions Act of 2014 (in the context of corporate acquisition activity)

LobbyistCovered position, as disclosed
JACQUELINE POMFRET KIRBY —
JOHN MYERS —
BELA SASTRY —

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); SENATE; Patent & Trademark Office (PTO); State, Dept of (DOS); U.S. Trade Representative (USTR)

Bills named: H.R. 4679 (113th)

Copyright/Patent/Trademark CPT

S 1720 - patent litigation reform; Issues related to intellectual property practices in foreign countries and impact on US entities

LobbyistCovered position, as disclosed
THERESA JOLIVETTE —
JACQUELINE POMFRET KIRBY —
BRADLEY ALLEN ROSSIN —
BELA SASTRY —

Contacted: State, Dept of (DOS); SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Commerce, Dept of (DOC)

Health Issues HCR

Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program; Issues related to pediatric medication access and impact of public guidelines on access; Issues related to oncology legislation,including medication affordability;Issues related to 21st Century Cures legislation and role of incentives in advancement of treatments and cures; Issues related to FDA and Biomedical Advanced Research Development Authority appropriations (no bill number) Medication adherence related legislation (no bill number) (Jennifer Snow and Christine Bloomquist were deleted from this and the prior amendment to this report because they did not meet the legal definition of lobbyists)

LobbyistCovered position, as disclosed
MARIA FIRVIDA —
THERESA JOLIVETTE —
JACQUELINE POMFRET KIRBY —
JOHN MYERS —
BELA SASTRY —

Contacted: State, Dept of (DOS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE; Patent & Trademark Office (PTO); U.S. Trade Representative (USTR)

Medicare/Medicaid MMM

H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes

LobbyistCovered position, as disclosed
THERESA JOLIVETTE —
JACQUELINE POMFRET KIRBY —
JOHN MYERS —
BELA SASTRY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); State, Dept of (DOS)

Bills named: H.R. 3590 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.